Abstract:Abstract Unrelated donor allogeneic hematopoietic stem cell transplantation (URD-HSCT) can potentially cure a variety of hematological malignancies. Until now, there were 140 cases of URD-HSCT in our bone marrow transplantation center, and we would retrospectively analyze the results of 128 patients received URD-HSCT between Nov. 1998 and May. 2006. The median age of all patients was 28 years (range 8–52 years), 27 patients with ALL in CR1, 28 patients with AML (26 in CR1 and 2 in CR2), 64 patients with CML (59 in CP, 1 in AP and 4 in BP), 8 patients with MDS, and 1 patient with MM. 113 patients were received Bu/Cy2 regimen as conditioning with busulfan 16mg/kg plus cyclophosphamide 120mg/kg, while other 5 patients with CML were received reduced intensity conditioning (RIC) regimen consisted of fludarabine (30mg/m2/d), busulfan (3.2mg/kg/d, i.v.) and ATG (5mg/kg/d). Graft with a median number of total nucleated cells was 3.45×108/kg (range 1.72–10.50×108/kg), including CD34+ cells 4.77×106/kg (range 0.72–9.92×106/kg) and CFU-GM 2.73×105/kg (range 1.46–7.91×105/kg). 110 patients were given MMF (0.5g/d), combined with CsA (3mg/kg/d) and short course MTX (10mg/m2/d) to prevent aGVHD. 18 patients received additional anti-CD25 monoclonal antibody 50mg/d on day 0, +4. Lipo protaglandin E1 was given to prevent SOS and CMV-PP65 antigen was monitored after the transplantation and ganciclovir was used to prevent CMV infection. Hemopoietic recovery was observed in 123 evaluable patients, and the median time to achieve ANC>0.5×109/L was 17 days (range 12–31 days), platelets >20×109/L was 24 days (range 8–140 days). aGVHD developed in 69 (56.10%) patients; aGVHD of grade I-II were observed in 53 (43.09%) patients and the severe aGVHD of grade III-IV were observed in 16 (13.01%) patients. cGVHD developed in 53 (46.49%) patients with 46 (40.35%) limited and 7 (6.14%) extensive. In group (n=110) which received MMF combined with CsA and MTX as aGVHD prophylaxis, aGVHD were observed in 60 (54.55%) patients with grade I-II 42.73% and grade III-IV 11.82%. While in group (n=18) which received additional anti-CD25 monoclonal antibody, aGVHD were observed in 7 (46.7%) patients with grade I-II 6 (33.3%) and grade III-IV 3 (16.67%). There was no significant difference between two regimen of aGVHD prophylaxis. Early TRM of all patients was 10.94% at 100 days after transplant. After a median follow-up of 13.2 months (range 1.3–92 months), clinical relapse were detected in 8 patients. By Kaplan-Meier method, the accumulative probability of 5-year overall survival of all patients was 60.98±4.52%, and which of ALL, AML, CML, MDS were 68.65±9.21%, 61.61±9.74%, 56.95±6.50% and 75.00±15.31%, respectively. 4 of 5 patients received reduced intensity URD-HSCT with follow-up of 7.3 months (range 3.0–10.3 months) experienced successful engraftment, and no aGVHD developed while cGVHD occurred in 2 cases, all patients achieved disease free survival. To further examined the impact of HLA matching on GVHD and survival, we compared the outcomes of the HLA-matched group (n=82) and HLA 1–2 alleles disparity mismatched group (n=46). aGVHD were observed in 38 (46.34%) patients in HLA-matched group and 31 (67.39%) patients in HLA-mismatched group (P<0.05), respectively. The survival of HLA-matched and HLA-mismatched group were 69.14% and 52.17% (P<0.05) respectively. URD-HSCT could be one of choice in patients with ALL, AML, CML, MDS, and HLA class I and class II matching would be associated with the outcomes of URD-HSCT.

Impacts of ABO Incompatibility on Early Outcome after Single Unit Unrelated Cord Blood Transplantation: a Retrospective Single Center Experience

Impact of HLA High-Resolution Matching on Outcomes of Myeloablative Unrelated Donor Hematopoietic Stem Cell Transplantation in Chinese Population

Preliminary results of multicenter studies on ABO-incompatible kidney transplantation

Abo不相容性和抗a / B异凝集素滴度对血液恶性肿瘤清髓处理后输血需求和无关脐带血移植的早期结果的影响

[Effect of ABO-incompatibility on Allogeneic Hematopoietic Stem Cell Transplantation].

Impact of donor-to-recipient ABO mismatch on outcomes of ATG-based peripheral blood stem cell-derived myeloablative conditioning haploidentical stem cell transplantation

[A comparison of clinical outcomes between HLA allele matched and 1 - 2 alleles mismatched unrelated allogeneic bone marrow transplantations].

Clinical retrospective analysis and long-term therapeutic effects of ABO-incompatible liver transplantation on type-O patients with acute severe liver disease

Impact of Donor-to-Recipient ABO Mismatch on Outcomes of Antithymocyte Globulin-Based Peripheral Blood Stem Cell-Derived Myeloablative Conditioning Haploidentical Stem Cell Transplantation.

Outcomes Of Unrelated Donor Hematopoietic Stem Cell Transplantation For Hematological Malignancy: A Single Center'S Experience.

Impact of ABO Incompatibility on Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

ABO-INCOMPATIBLE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION TREATMENT OF MALIGNANT HEMATOLOGIC DISEASES

Diagnosis of coccidioidomycosis.

Comparative Outcomes Between Cord Blood Transplantation and Bone Marrow or Peripheral Blood Stem Cell Transplantation from Unrelated Donors in Patients with Hematologic Malignancies: a Single-Institute Analysis.

Effect of Different Induction Therapies on the Clinical Outcomes of ABO-incompatible Living Donor Kidney Transplantation Recipients

Clinical outcomes of unrelated cord blood transplantation in children with malignant and non-malignant diseases: Multicenter experience in China.

Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation

Unrelated Donor Umbilical Cord Blood Transplantation Versus Unrelated Donor Bone Marrow Transplantation in Adult and Pediatric Patients: A Meta-Analysis

ABO‐incompatible Living Kidney Transplantation

Impact of Abo Incompatibility on Patients' Outcome after Haploidentical Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia - A Report from the Acute Leukemia Working Party of the Ebmt

Long-term Outcomes in Adults with Leukemia Treated with Transplantation of Two Unrelated Umbilical Cord Blood Units.